TAK-875 Versus Placebo or Glimepiride in Type 2 Diabetes Mellitus:

by Dr.Chhavi on  March 19, 2012 at 3:10 PM Health In Focus   - G J E 4
New drug targets have been under research in order to explore alternative drugs to promote insulin secretion in patients with type-2 diabetes mellitus. One of the most researched targets amongst these is the G-protein coupled receptor-40 (GPCR-40) or free-fatty acid receptor-1 (FFAR1). GPCR-40 or the FFAR1 is found in the pancreatic β-cells, which secrete insulin.
TAK-875 Versus Placebo or Glimepiride in Type 2 Diabetes Mellitus:
TAK-875 Versus Placebo or Glimepiride in Type 2 Diabetes Mellitus:

The FFAR1 receptors are activated by short and long-chain free fatty acids. Thus, they are activated when the free fatty acid levels in the blood are high, for example, after a meal. The activation results in insulin secretion. The FFAR1 receptors have been explored as a target for the treatment of diabetes

A phase-2 clinical trial was recently completed which assessed the potential of TAK-875 in achieving control of blood glucose levels without causing hypoglycemia or low sugar levels TAK-875 brings about its action by the activation of FFAR1 receptors.

Four hundred and twenty six patients with type-2 diabetes mellitus were included in this study. These were patients who did not respond to diet or metformin. The patients were divided randomly into three study groups: the first group which received TAK-875, the second group received glimepiride 4 mg once daily and the third group received placebo for over a period of twelve weeks.

The achievement of glycaemic control was measured using the gylcosylated haemoglobin percentage (HbA1c) from the baseline till the end of the study.

A significant reduction in HbA1c was observed by the researchers in the group receiving TAK-875.

The researchers also observed that hypoglycemic events were reported to be higher in the group receiving glimepiride as compared to placebo or TAK-875.

The researchers thus concluded that activation of FFAR1 is a viable therapeutic target for the treatment of type 2 diabetes mellitus.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like